Being a potent cancer proliferation driver (27), MYCN amplification contributes to the highly proliferative, malignant nature of the IMR-32 NB cells, which HSP90 inhibition with 17-AAG sufficiently abrogated. This evidence concerns the gene MYCN and cancer.